Ultrasound drugs expected to receive stricter warning labels

10/7/2007 | Wall Street Journal, The

Bristol-Myers Squibb Co.'s Definity, General Electric Co.'s Optison and several other drugs used with ultrasound imaging machines to diagnose heart diseases may come with stronger, black-box warning labels to tell doctors not to use the drugs in patients with unstable angina, acute heart attacks and unstable cardiopulmonary disease and to monitor patients' heartbeats for trouble with an electrocardiogram, sources said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park